Welcome to our dedicated page for abrdn Life Sciences Investors SEC filings (Ticker: HQL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on abrdn Life Sciences Investors's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into abrdn Life Sciences Investors's regulatory disclosures and financial reporting.
Saba Capital Management, L.P. reported insider sales of 700 shares of abrdn Life Sciences Investors (HQL) on 09/15/2025 at $14.13 and 2,026 shares on 09/16/2025 at $13.99. After these transactions the filer beneficially owned 2,950,781 shares indirectly. The filing lists the reporting relationship as a Director and is signed by Zachary Gindes and Boaz Weinstein on 09/17/2025. No derivative transactions were reported.
Saba Capital Management, L.P. reported insider sales of 700 shares of abrdn Life Sciences Investors (HQL) on 09/15/2025 at $14.13 and 2,026 shares on 09/16/2025 at $13.99. After these transactions the filer beneficially owned 2,950,781 shares indirectly. The filing lists the reporting relationship as a Director and is signed by Zachary Gindes and Boaz Weinstein on 09/17/2025. No derivative transactions were reported.
Saba Capital Management, L.P. reported a Form 4 showing an insider sale of 15,116 shares of abrdn Life Sciences Investors (HQL) on 09/11/2025 at a price of $14.28 per share. After the transaction, the reporting person beneficially owned 2,953,507 shares indirectly. The filing reflects compliance with Section 16 reporting for a director-level reporting person.
Saba Capital Management, L.P. reported a Form 4 showing an insider sale of 15,116 shares of abrdn Life Sciences Investors (HQL) on 09/11/2025 at a price of $14.28 per share. After the transaction, the reporting person beneficially owned 2,953,507 shares indirectly. The filing reflects compliance with Section 16 reporting for a director-level reporting person.
abrdn Life Sciences Investors (HQL) insiders reported an indirect sale of common stock. On 09/02/2025 Saba Capital Management, L.P. and Boaz Weinstein reported a disposition of 14,083 shares at $14.04 per share. After the sale, the reporting persons beneficially owned 2,968,623 shares indirectly. The Form 4 was filed by more than one reporting person and signed on 09/04/2025.
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly report beneficial ownership of 2,982,706 common shares of abrdn Life Sciences Investors (ticker HQL), representing 10.33% of the outstanding common shares based on 28,872,416 shares as of March 31, 2025. The Reporting Persons state approximately $39,115,994 was paid to acquire these shares, funded from investor subscriptions, capital appreciation and margin borrowings. The filing is Amendment No. 7 to a Schedule 13D/A and updates Items 3, 5 and 7; the Reporting Persons assert no specific purpose for the holdings and indicate dividends and sale proceeds flow to the advised funds.
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly report beneficial ownership of 2,982,706 common shares of abrdn Life Sciences Investors (ticker HQL), representing 10.33% of the outstanding common shares based on 28,872,416 shares as of March 31, 2025. The Reporting Persons state approximately $39,115,994 was paid to acquire these shares, funded from investor subscriptions, capital appreciation and margin borrowings. The filing is Amendment No. 7 to a Schedule 13D/A and updates Items 3, 5 and 7; the Reporting Persons assert no specific purpose for the holdings and indicate dividends and sale proceeds flow to the advised funds.
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly report beneficial ownership of 2,982,706 common shares of abrdn Life Sciences Investors (ticker HQL), representing 10.33% of the outstanding common shares based on 28,872,416 shares as of March 31, 2025. The Reporting Persons state approximately $39,115,994 was paid to acquire these shares, funded from investor subscriptions, capital appreciation and margin borrowings. The filing is Amendment No. 7 to a Schedule 13D/A and updates Items 3, 5 and 7; the Reporting Persons assert no specific purpose for the holdings and indicate dividends and sale proceeds flow to the advised funds.
Saba Capital Management and individual reporting person Boaz Weinstein disclosed an insider sale in abrdn Life Sciences Investors (HQL). On 08/29/2025 they sold 23,723 shares of common stock at an average price of $13.89 per share. After the transaction, the reporting persons beneficially owned 2,982,706 shares indirectly. The Form 4 identifies the reporting persons as a director and a 10% owner and is signed on 09/02/2025.
Saba Capital Management, L.P. and individual reporting person Boaz Weinstein disclosed a small insider sale of abrdn Life Sciences Investors (HQL) common stock. On 08/26/2025 400 shares were sold at $13.83 per share. After the transaction the reporting entities beneficially owned 3,006,429 shares on an indirect basis. The filing identifies the reporters as a director and 10% owner.
abrdn Life Sciences Investors (HQL) insiders Saba Capital Management, L.P. and Boaz Weinstein reported a sale of common stock on 08/21/2025. The filing shows a disposition of 10,710 shares at a price of $14.07 per share. After the reported transaction, the reporting persons beneficially own 3,006,829 shares indirectly. The Form 4 is signed and dated 08/25/2025 and was filed as a joint report by more than one reporting person. No derivative transactions were reported in this filing.